News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
410,286 Results
Type
Article (17871)
Company Profile (119)
Press Release (392296)
Multimedia
Podcasts (55)
Webinars (11)
Section
Business (135923)
Career Advice (868)
Deals (24671)
Drug Delivery (70)
Drug Development (47778)
Employer Resources (70)
FDA (8707)
Job Trends (8647)
News (221129)
Policy (18755)
Tag
Academia (696)
Accelerated approval (2)
Adcomms (9)
Allergies (47)
Alliances (31506)
ALS (51)
Alzheimer's disease (590)
Antibody-drug conjugate (ADC) (61)
Approvals (8758)
Artificial intelligence (152)
Autoimmune disease (12)
Automation (7)
Bankruptcy (212)
Best Places to Work (6157)
BIOSECURE Act (10)
Biosimilars (74)
Biotechnology (56)
Bladder cancer (33)
Brain cancer (20)
Breast cancer (134)
Cancer (1159)
Cardiovascular disease (107)
Career advice (746)
Career pathing (14)
CAR-T (64)
CDC (4)
Cell therapy (195)
Cervical cancer (7)
Clinical research (40247)
Collaboration (522)
Compensation (331)
Complete response letters (17)
COVID-19 (987)
CRISPR (37)
C-suite (224)
Cystic fibrosis (56)
Data (1287)
Denatured (15)
Depression (20)
Diabetes (130)
Diagnostics (2937)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (20)
Drug discovery (73)
Drug pricing (87)
Drug shortages (12)
Duchenne muscular dystrophy (57)
Earnings (58760)
Editorial (20)
Employer branding (13)
Employer resources (66)
Events (63986)
Executive appointments (633)
FDA (9460)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (415)
Gene editing (60)
Generative AI (11)
Gene therapy (171)
GLP-1 (441)
Government (1657)
Grass and pollen (3)
Guidances (120)
Healthcare (7486)
Huntington's disease (10)
IgA nephropathy (21)
Immunology and inflammation (61)
Immuno-oncology (3)
Indications (22)
Infectious disease (1036)
Inflammatory bowel disease (74)
Inflation Reduction Act (6)
Influenza (17)
Intellectual property (66)
Interviews (109)
IPO (11080)
IRA (34)
Job creations (2745)
Job search strategy (681)
Kidney cancer (10)
Labor market (21)
Layoffs (279)
Leadership (9)
Legal (5077)
Liver cancer (34)
Lung cancer (160)
Lymphoma (92)
Machine learning (4)
Management (22)
Manufacturing (231)
MASH (57)
Medical device (4721)
Medtech (4724)
Mergers & acquisitions (14005)
Metabolic disorders (397)
Multiple sclerosis (34)
NASH (17)
Neurodegenerative disease (44)
Neuropsychiatric disorders (11)
Neuroscience (882)
NextGen: Class of 2025 (2868)
Non-profit (1190)
Now hiring (13)
Obesity (210)
Opinion (157)
Ovarian cancer (34)
Pain (74)
Pancreatic cancer (38)
Parkinson's disease (72)
Partnered (10)
Patents (154)
Patient recruitment (61)
Peanut (17)
People (41195)
Pharmaceutical (65)
Pharmacy benefit managers (13)
Phase I (11174)
Phase II (17286)
Phase III (14665)
Pipeline (1065)
Policy (102)
Postmarket research (1729)
Preclinical (4495)
Press Release (72)
Prostate cancer (74)
Psychedelics (11)
Radiopharmaceuticals (181)
Rare diseases (249)
Real estate (3789)
Recruiting (26)
Regulatory (13222)
Reports (23)
Research institute (790)
Resumes & cover letters (126)
Rett syndrome (9)
RNA editing (4)
RSV (8)
Schizophrenia (52)
Series A (73)
Series B (41)
Service/supplier (3)
Sickle cell disease (37)
Special edition (8)
Spinal muscular atrophy (115)
Sponsored (13)
Startups (2221)
State (2)
Stomach cancer (5)
Supply chain (39)
Tariffs (47)
The Weekly (38)
Vaccines (210)
Venture capitalists (22)
Weight loss (121)
Women's health (11)
Worklife (4)
Date
Today (79)
Last 7 days (280)
Last 30 days (1273)
Last 365 days (17422)
2025 (8351)
2024 (19565)
2023 (22809)
2022 (31095)
2021 (32578)
2020 (30638)
2019 (23683)
2018 (18364)
2017 (19761)
2016 (18575)
2015 (22496)
2014 (18492)
2013 (15579)
2012 (16767)
2011 (17457)
2010 (16480)
Location
Africa (441)
Alabama (28)
Alaska (3)
Arizona (96)
Arkansas (4)
Asia (26636)
Australia (3537)
California (3640)
Canada (1407)
China (366)
Colorado (164)
Connecticut (158)
Delaware (100)
Europe (54193)
Florida (626)
Georgia (71)
Idaho (28)
Illinois (312)
India (18)
Indiana (196)
Iowa (8)
Japan (158)
Kansas (74)
Kentucky (22)
Louisiana (8)
Maine (45)
Maryland (437)
Massachusetts (2954)
Michigan (112)
Minnesota (209)
Mississippi (2)
Missouri (40)
Montana (17)
Nebraska (13)
Nevada (37)
New Hampshire (23)
New Jersey (1273)
New Mexico (11)
New York (991)
North Carolina (644)
North Dakota (5)
Northern California (1616)
Ohio (111)
Oklahoma (6)
Oregon (19)
Pennsylvania (752)
Puerto Rico (10)
Rhode Island (18)
South America (670)
South Carolina (14)
Southern California (1416)
Tennessee (74)
Texas (486)
United States (13968)
Utah (90)
Virginia (133)
Washington D.C. (42)
Washington State (276)
West Virginia (3)
Wisconsin (37)
410,286 Results for "novartis pharmaceuticals corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Legal
Former Chinook Board Member Indicted for Insider Trading Related to $3.2B Novartis Buy
Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider trading.
May 28, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Venture capitalists
The Top 5 Most Active Corporate VCs in Pharma
BioSpace
examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made headlines last year with its $16.5 billion Catalent buy, topped the list.
May 21, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
May 27, 2025
·
9 min read
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
1 of 41,029
Next
